Follistatin-Like 1 Promotes Bleomycin-Induced Pulmonary Fibrosis Through the Transforming Growth Factor Beta 1/Mitogen-Activated Protein Kinase Signaling Pathway
Pulmonary fibrosis is a progressive and often fatal lung disease characterized by the excessive deposition of extracellular matrix components, leading to the destruction of lung architecture and impaired gas exchange. The pathogenesis of pulmonary fibrosis involves complex interactions between various cell types, cytokines, and signaling pathways. Among these, the transforming growth factor-beta 1 (TGF-β1) signaling pathway plays a central role in promoting fibrosis. This study investigates the role of Follistatin-like 1 (FSTL1) in bleomycin-induced pulmonary fibrosis and its interaction with the TGF-β1/mitogen-activated protein kinase (MAPK) signaling pathway.
FSTL1 is a secreted glycoprotein that has been implicated in various biological processes, including inflammation, tissue repair, and fibrosis. Previous studies have suggested that FSTL1 may play a role in the pathogenesis of fibrotic diseases, but the underlying mechanisms remain poorly understood. In this study, the authors aimed to elucidate the role of FSTL1 in pulmonary fibrosis and to explore its potential as a therapeutic target.
The study utilized a bleomycin-induced pulmonary fibrosis model in mice, which is a well-established model for studying the mechanisms of pulmonary fibrosis. Bleomycin was administered intratracheally to induce lung injury and fibrosis. The expression of FSTL1 was assessed in lung tissues from bleomycin-treated mice and compared to control mice. The results showed that FSTL1 expression was significantly upregulated in the lungs of bleomycin-treated mice, suggesting a potential role for FSTL1 in the pathogenesis of pulmonary fibrosis.
To further investigate the role of FSTL1 in pulmonary fibrosis, the authors examined the effects of FSTL1 on lung fibroblasts, which are key effector cells in fibrosis. Mouse lung fibroblast cells (MLgs) were treated with recombinant FSTL1, and the effects on cell proliferation, migration, and invasion were assessed. The results demonstrated that FSTL1 significantly promoted the proliferation, migration, and invasion of MLgs, indicating that FSTL1 may contribute to fibrosis by enhancing fibroblast activity.
Next, the authors explored the signaling pathways through which FSTL1 exerts its effects on fibroblasts. The TGF-β1/MAPK signaling pathway is known to play a critical role in fibrosis, and the authors hypothesized that FSTL1 may interact with this pathway. To test this hypothesis, MLgs were treated with FSTL1 in the presence or absence of specific inhibitors of the MAPK pathway, including U0126 (an ERK inhibitor), SB202190 (a p38 inhibitor), SP600125 (a JNK inhibitor), and SB525334 (a Smad2/3 inhibitor). The results showed that FSTL1-induced fibroblast proliferation, migration, and invasion were significantly attenuated by these inhibitors, suggesting that FSTL1 promotes fibrosis through the activation of the MAPK pathway.
To further confirm the involvement of the MAPK pathway, the authors examined the phosphorylation status of key signaling molecules in the MAPK pathway, including p38, JNK, and Smad2/3, in FSTL1-treated MLgs. The results demonstrated that FSTL1 treatment led to the phosphorylation of p38, JNK, and Smad2/3, indicating that FSTL1 activates the MAPK pathway in fibroblasts.
In addition to its effects on fibroblasts, the authors also investigated the role of FSTL1 in the regulation of TGF-β1 expression. TGF-β1 is a potent profibrotic cytokine that plays a central role in the pathogenesis of pulmonary fibrosis. The authors found that FSTL1 treatment significantly increased the expression of TGF-β1 in MLgs, suggesting that FSTL1 may promote fibrosis by upregulating TGF-β1 expression.
To further explore the relationship between FSTL1 and TGF-β1, the authors examined the effects of TGF-β1 on FSTL1 expression in MLgs. The results showed that TGF-β1 treatment significantly increased the expression of FSTL1, indicating a positive feedback loop between FSTL1 and TGF-β1 in the regulation of fibrosis.
The authors also investigated the effects of FSTL1 on the expression of extracellular matrix components, which are key contributors to fibrosis. The results showed that FSTL1 treatment significantly increased the expression of collagen I and fibronectin in MLgs, further supporting the role of FSTL1 in promoting fibrosis.
Finally, the authors examined the effects of FSTL1 inhibition on bleomycin-induced pulmonary fibrosis in mice. Mice were treated with a neutralizing antibody against FSTL1, and the effects on lung fibrosis were assessed. The results showed that FSTL1 inhibition significantly attenuated bleomycin-induced lung fibrosis, as evidenced by reduced collagen deposition and improved lung function.
In conclusion, this study demonstrates that FSTL1 plays a critical role in the pathogenesis of bleomycin-induced pulmonary fibrosis by promoting fibroblast proliferation, migration, and invasion through the activation of the TGF-β1/MAPK signaling pathway. The findings suggest that FSTL1 may serve as a potential therapeutic target for the treatment of pulmonary fibrosis. Further studies are needed to explore the therapeutic potential of FSTL1 inhibition in other models of pulmonary fibrosis and in human patients.
doi.org/10.4103/0366-6999.238151
Was this helpful?
0 / 0